FDA: Selzentry approved for pediatric use

November 09, 2016

On Friday November 4, 2016, FDA approved Selzentry (maraviroc) 20 mg/mL oral solution, Selzentry (maraviroc) 25 mg and 75 mg tablets and updated the label to include use in pediatric patients 2 years of age and older weighing at least 10 kg.

The major changes to the label are summarized here.

Original Article

Post Views: 545

Phase 1 clinical program of ABI-H0731 for hepatitis B initiated

HIV-positive people may lose more years of life from smoking than from HIV/AIDS

FDA: Selzentry approved for pediatric use

Related News

Behavioral intervention reduces HIV transmission risk in young transgender women

Global progress towards hepatitis C elimination still blocked by cost of treatment, lack of diagnosis

Vladimir Zhovtyak: European AIDS conference is a step forward to control the HIV/AIDS in Europe

Patient Communities Agree on Shared Vision of HIV Treatment Regimen

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection